| Biomarker ID | 1665 |
| PMID | 25807461 |
| Year | 2015 |
| Biomarker | PLZF (Promyelocytic leukemia zinc finger protein) |
| Biomarker Basis | Expression Based |
| Biomolecule | Protein |
| Source | Tissue |
| Subjects | Humans |
| Regulation | High expression associated with shorter disease-free survival time |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | Pathway include: Class I MHC mediated antigen processing and presentation; NF-kappaB Signaling; Endometrial cancer; Pathways in cancer; Transcriptional misregulation in cancer |
| Experiment | Normal Vs Primary and Metastatic PCa |
| Type of Biomarker | Diagnostic |
| Cohort | 83 primary PCa from biopsies, 43 metastatic PCa and 8 paired primary and metastatic PCa were included in the analysis |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | NA |
| Method Used | Immunohistochemistry |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | NA |